[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369547-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369547-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cd44-a-key-regulator-of-iron-metabolism-redox-balance-and-therapeutic-resistance-in-cancer-stem-cells","CD44 - a key regulator of iron metabolism, redox balance, and therapeutic resistance in cancer stem cells","","CD44, a multifunctional cell surface protein, is a central regulator in cancer stem cell biology, coordinating stemness, metabolic reprogramming, and therapeutic resistance. Studies show CD44 drives ferroptosis resistance by stabilizing SLC7A11 (xCT), strengthening antioxidant defense to help cancer stem cells withstand oxidative stress while maintaining tumorigenic potential. CD44 also shapes intracellular iron metabolism and redox balance, supporting survival in stressful microenvironments. Therapeutic approaches targeting CD44, including ferroptosis inducers, combination therapies, CD44-mediated nanocarriers, and metabolic inhibitors, demonstrate strong preclinical and early clinical promise. Regulatory plasticity of CD44 isoforms further supports the need for context-specific interventions. This review emphasizes CD44’s roles in ferroptosis resistance, iron metabolism, and redox control, offering a framework to overcome resistance in refractory cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cd44-a-key-regulator-of-iron-metabolism-redox-balance-and-therapeutic-resistance-in-cancer-stem-cells/369547/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cd44-a-key-regulator-of-iron-metabolism-redox-balance-and-therapeutic-resistance-in-cancer-stem-cells/369547.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn Holloway","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does CD44 contribute to therapeutic resistance in cancer stem cells?","Question",{"text":63,"@type":64},"CD44 coordinates stemness and supports survival under stress, including resistance to therapeutic pressure. It integrates regulation of redox state and intracellular iron metabolism that helps cancer stem cells evade damage.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is CD44’s role in ferroptosis resistance?",{"text":68,"@type":64},"CD44 promotes ferroptosis resistance by stabilizing SLC7A11 (xCT), a key antioxidant defense component. This enables cancer stem cells to escape oxidative stress and sustain tumorigenic potential.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is targeting CD44 considered promising for cancer treatment?",{"text":72,"@type":64},"Targeting CD44 can disrupt ferroptosis resistance and related iron/redox regulatory pathways that cancer stem cells rely on. The review highlights emerging strategies such as CD44-directed therapies, nanocarriers, and metabolic inhibitors with preclinical and early clinical potential.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369547,1790330498,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":118,"preview_page_count":33,"preview_urls":144},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","CD44: a key regulator of iron metabolism, redox balance, and therapeutic resistance in cancer stem cells  \nTaijuAndo1,2, Juntaro Yamasaki1, Hideyuki Saya1, Osamu Nagano*, 1,  \n1Division of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Japan,  \n2Department of Medical Oncology, Fujita Health University Hospital, Toyoake 470-1192, Japan.  \n*Corresponding author: Osamu Nagano, DDS, PhD, Division of Gene Regulation, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan ([osamu.nagano@fujita-hu.ac.jp](osamu.nagano@fujita-hu.ac.jp))  \nAbstract  \nCD44, a multifunctional cell surface protein, has emerged as a pivotal regulator in cancer stem cell (CSC) biology, orchestrating processes such as stemness, metabolic reprogramming, and therapeutic resistance. Recent studies have identified a critical role of CD44 in ferroptosis resistance by stabilizing SLC7A11 (xCT), a key component of the antioxidant defense system, enabling CSCs to evade oxidative stress and sustain tumorigenic potential. Additionally, CD44 regulates intracellular iron metabolism and redox balance, further supporting CSC survival and adaptation to stressful microenvironments. Therapeutic strategies targeting CD44, including ferroptosis inducers and combination therapies, have shown significant potential in preclinical and early clinical settings. Innovations such as CD44-mediated nanocarriers and metabolic inhibitors present novel opportunities to disrupt CSC-associated resistance mechanisms. Furthermore, the dynamic plasticity of CD44 isoforms governed by transcriptional, post-transcriptional, and epigenetic regulation underscores the importance of context-specific therapeutic approaches. This review highlights the multifaceted roles of CD44 in CSC biology, focusing on its contribution to ferroptosis resistance, iron metabolism, and redox regulation. Targeting CD44 offers a promising avenue for overcoming therapeutic resistance and improving the outcomes of refractory cancers. Future studies are needed to refine these strategies and enable their clinical translation.  \nKey words: CD44; cancer stem cell; iron metabolism; ferroptosis; SLC7A11 .  \nGraphical Abstract  \nSignificance statement  \nEmerging evidence suggests that iron metabolism and redox regulation are intimately linked to cancer stemness and therapeutic resistance. This article highlights a previously underappreciated role of CD44 in orchestrating these processes within cancer stem cells. By integrating recent advances across redox biology, iron homeostasis, and stem cell regulation, we propose a unifying framework in which CD44 acts as a central node in therapy resistance. These insights provide a conceptual basis for future therapeutic strategies targeting the metabolic vulnerabilities of cancer stem cells.  \nIntroduction  \nSince Bonnet et al. first identified and isolated cancer stem cells (CSCs) from human acute myeloid leukemia in 1997,1 CSCs  \nhave attracted significant attention owing to their unique capabilities for self-renewal and differentiation into progeny. CSCs possess a distinct cellular milieu defined by the specific  \nReceived: 17 December 2024; Accepted: 4 April 2025.  \n© The Author(s) 2025. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \n2 Stem Cells, 2025, Vol. 43, No. 6  \ngene expression profiles and unique metabolic pathways, enabling them to withstand various environmental stresses and drive invasion and metastasis into new microenvironments. CSCs can survive cancer drug treatment through mechanisms suc","cbCaik6TbX5YAVRg","https://ap.wps.com/l/cbCaik6TbX5YAVRg","pdf",697072,"English","# Abstract\n# Significance statement\n# Introduction","[{\"question\":\"How does CD44 contribute to therapeutic resistance in cancer stem cells?\",\"answer\":\"CD44 coordinates stemness and supports survival under stress, including resistance to therapeutic pressure. It integrates regulation of redox state and intracellular iron metabolism that helps cancer stem cells evade damage.\"},{\"question\":\"What is CD44’s role in ferroptosis resistance?\",\"answer\":\"CD44 promotes ferroptosis resistance by stabilizing SLC7A11 (xCT), a key antioxidant defense component. This enables cancer stem cells to escape oxidative stress and sustain tumorigenic potential.\"},{\"question\":\"Why is targeting CD44 considered promising for cancer treatment?\",\"answer\":\"Targeting CD44 can disrupt ferroptosis resistance and related iron/redox regulatory pathways that cancer stem cells rely on. The review highlights emerging strategies such as CD44-directed therapies, nanocarriers, and metabolic inhibitors with preclinical and early clinical potential.\"}]","CD44 - a key regulator of iron metabolism, redox balance, and therapeutic resistance in cancer stem cells | PDF",1790183333,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a58e5725a08c785fd91a2b6ed58960aa.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8bed289d67fd03e1f67599b46beb36f.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b31f21ec1d508ce0e262dc65610036c5.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14c7d486a639b6f08c48184b640cfcb6.webp",980,1287]